Dr. Stephen Ong, MD
Family Medicine (Family Medicine Physician)
6357 Oxon Hill Rd
Oxon Hill, MD 20745
Who else practices at this address →
Prince George's County includes primary care (19% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 56
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 197
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
MD license D014760 -
Surgery Physician
DC license MD6423
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 197
- Services billed
- 1,348
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 292 | 163 |
| Annual alcohol misuse screening, 5 to 15 minutes | 144 | 144 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 139 | 139 |
| Established patient office or other outpatient visit, 20-29 minutes | 139 | 99 |
| Annual depression screening, 5 to 15 minutes | 119 | 119 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 117 | 110 |
| Advance care planning, first 30 minutes | 84 | 82 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 60 | 60 |
| Administration of influenza virus vaccine | 60 | 60 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 41 | 41 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 40 payments worth $3,824 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,713 |
|---|---|
| Amgen Inc. | $1,621 |
| Novo Nordisk Inc | $156 |
| Cvrx, Inc. | $99.51 |
| Bayer HealthCare Pharmaceuticals Inc. | $52.95 |
| Lilly USA, LLC | $47.29 |
| Pfizer Inc. | $44.36 |
| Sumitomo Pharma America, Inc. | $27.82 |
| Travel and Lodging | $2,261 |
|---|---|
| Food and Beverage | $1,563 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jul 23, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $613 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 28, 2025 | Travel and Lodging travel to Fort Lauderdale, FL · in-kind | $563 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 10, 2025 | Travel and Lodging travel to Fort Lauderdale, FL · in-kind | $514 |
| Amgen Inc. Jul 23, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $375 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 18, 2025 | Travel and Lodging travel to Fort Lauderdale, FL · in-kind | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 31, 2025 | Travel and Lodging travel to Fort Lauderdale, FL · in-kind | $56.53 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 11 companies. The companies reported $1,135,840 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A phase 3 randomized placebocontrolled observerblinded trial to evaluate the safety of a 6VALENT ospabased lyme disease vaccine VLA15 in healthy children 5 through 17 years of age
Pfizer Inc. - A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM
Amgen Inc. - A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension
Novartis Pharmaceuticals Corporation - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.